Cantor Fitzgerald Initiates Coverage On Humacyte with Overweight Rating, Announces Price Target of $6
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Humacyte (NASDAQ:HUMA) with an Overweight rating and a price target of $6.
June 22, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald initiates coverage on Humacyte with an Overweight rating and a price target of $6.
Cantor Fitzgerald's initiation of coverage on Humacyte with an Overweight rating and a price target of $6 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100